Skip to main content
Article thumbnail
Location of Repository

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy

By Kalathil K Sureshkumar

Abstract

Hypertension is a major risk factor for the development of cardiovascular and renal disease. The incidence of hypertension is increasing globally and the rate of blood pressure control remains inadequate. Renin-angiotensin-aldosterone system (RAAS) plays a crucial role in volume regulation and maintenance of blood pressure. Pathological activation of RAAS results in chronic hypertension and consequent end organ damage. Most patients with hypertension require combination therapy using agents with complimentary mechanisms of action. Hydrochlorothiazide (HCTZ) together with an agent blocking the RAAS such as an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) are widely used effective anti-hypertensive therapy. Aliskiren is an orally effective direct renin inhibitor that blocks the generation of angiotensin I from angiotensinogen, the rate limiting step of RAAS activation. Studies have shown equivalent antihypertensive efficacy of aliskiren when compared to existing medications such as HCTZ, ACE inhibitors and ARBs. Aliskiren has also been tested in combination therapies. The current review aims to look at the efficacy of aliskiren therapy in hypertension and the evidence for using aliskiren in combination with HCTZ

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2663460
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2007). A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
    2. (2007). Absorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos,
    3. (2005). Aliksiren, a novel orally effective renin inhibitir, provides dose-dependent antihypertensive effi cacy and placebo-like tolerability in hypertensive patients.
    4. (2008). Aliskiren combined with losartan in type 2 diabetes and nephropathy.
    5. (2007). Aliskiren reduced blood pressure and suppress plasma renin activity in combination with a thiazide diuretic, an angiotensin converting enzyme inhibitor, or an angiotensin receptor blocker.
    6. (2007). Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazidebased therapy in patients with hypertension. J Clin Hypertens, 9(Suppl A):A182.
    7. (2007). Aliskiren, a direct renin inhibitor, provides antihypertensive effi cacy and excellent tolerability independent of age or gender in patients with hypertension.
    8. (2006). Aliskiren, a novel oral renin inhibitor, provides dose-dependent effi cacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res,
    9. (2007). Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats.
    10. (2006). Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J,
    11. (2007). Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.
    12. (2007). Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    13. (2006). Aliskiren, the fi rst in a new class of orally effective renin inhibitors, has no clinically signifi -cant interactions with digoxin in healthy volunteers. Clin Pharmacol Ther,
    14. (2007). Aliskiren, the fi rst renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.
    15. (1997). Angiotensin (1–7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide.
    16. (1996). Angiotensin (1–7) inhibits vascular smooth muscle growth.
    17. (1994). Angiotensin (1–7) is an antagonist at the type 1 angiotensin II receptor.
    18. (2005). Angiotensin II and the endothelium: diverse signals and effects.
    19. (2001). Angiotensin II and the pathophysiology of cardiovascular remodeling.
    20. (2002). Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100); Comparison with enalapril. Hypertension,
    21. (2007). Antihypertensive effi cacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy.
    22. (2007). Antihypertensive effi cacy, safety, and tolrability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis.
    23. (2000). Combination antihypertensive drugs: recommendations for use. Am Fam Physician,
    24. (2003). Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretic in hypertension. Expert Rev Cardiovascular Ther,
    25. (2008). Comparative effi cacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
    26. (2005). Compliment activation in angiotensin II induced organdamge. Circ Res,
    27. (1998). Determinant so finterindividual variation of renin and pro-renin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans.
    28. (2007). Direct renin inhibition with aliskiren in obese patients with arterial hypertension.
    29. (2008). Effect of aliskiren on blood pressure, albuminuria, and(pro)renin receptor expression in diabetic TG(mRen-2) rats.
    30. (2008). Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab, (Epub ahead of print).
    31. (2004). Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in health subjects.
    32. (1996). Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension.
    33. (2007). Effi cacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial.
    34. (2007). Effi cacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    35. (2005). Global burden of hypertension: analysis of worldwide data.
    36. Haber E.1974. The renin angiotensin system.
    37. (2004). Hypertension treatment and control in fi ve European countries, Canada and the United States. Hypertension,
    38. (1990). Identifi cation of a highly specifi c chymase as the major angiotensin II forming enzyme in the human heart.
    39. (1985). Increased plasma inactive renin in diabetes mellitus a marker of microvascular complications.
    40. (2001). Is there a future for renin inhibitors? Exp Opin Invest Drugs,
    41. (2006). Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    42. (1993). Levels of angiotensin and molecular biology of the tissue angiotensin systems. Regul Pept,
    43. (2008). Long-term safety, tolerability and effi cacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin,
    44. (2000). Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev,
    45. (1994). Natriuretic action of angiotensin (1–7).
    46. O’Brien E.2003. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
    47. (1998). Pathways of angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system.
    48. (2005). Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.
    49. (2007). Pharmacokinetics, safety and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.
    50. (2004). Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1-receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    51. (2002). Pivotal role of the renin/ pro-renin receptor in angiotensin II production and cellular responses to renin.
    52. (2001). Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr Nephrol,
    53. (1997). Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients.
    54. (2007). Prevalence, awareness, treatment and control of hypertension among United States adults 1999–2004.
    55. (2006). Pro-renin induces intracellular signaling in cardiomyocytes independently of angiotensin II.
    56. (2008). Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren.
    57. (2007). Regression of nephropathy developed in diabetes by (pro)renin receptor blockade.
    58. (2008). Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
    59. (2008). Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
    60. (2007). Renin inhibition with aliskiren provides additive antihypertensive effi cacy when used in combination with hydrochlorothiazide.
    61. (2006). Renin inhibition with aliskiren: where are we now and where are we going?
    62. (2005). Renin, pro-renin and the putative (pro)renin receptor.
    63. (2007). Safety and effi cacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension.
    64. (1993). Single drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The department of Veterans Affairs Cooperative Study Group on Antihypertensive agents.
    65. Soc Nephrol,
    66. (1992). Species specifi city of renin kinetics in transgenic rats harboring the human renin and angiotensin genes.
    67. (2003). Structure based design of aliskiren, a novel orally effective renin inhibitor.
    68. (2002). Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    69. (2007). Tecturna® (aliskiren tablets): US prescribing information. East
    70. (2007). The diffi cult conception, birth and delivery of renin inhibitor: controversies around aliskiren.
    71. (2007). The potential role of pro-renin in diabetic nephropathy.
    72. Theodore Cooper Memorial Lecture. A mouse view of hypertension.
    73. (2001). Tissue angiotensin and pathophysiology of vascuklar disease, a unifying hypothesis.
    74. (1998). Vasodepressor actions of angiotensin (1–7) unmasked during combine treatment with lisinopril and losartan.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.